Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL: A case series of five pediatric, adolescent and young adult patients

Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL: A case series of five pediatric, adolescent and young adult patients

Abstract Background The development of tyrosine kinase inhibitors (TKIs) has significantly improved survival rates among patients with Philadelphia chromosome (Ph+) B cell acute lymphoblastic leukemia (B‐ALL). Ph‐like B‐ALL patients lack the BCR::ABL1 translocation but share gene expression profiles...

Full description

Bibliographic Details
Main Authors: Savannah S. Shumock, William C. Temple, Amanda Marinoff, Kathryn Aaronson, Erica Southworth, Simayijiang Xirenayi, Alex G. Lee, Stanley G. Leung, E. Alejandro Sweet‐Cordero, Michelle Hermiston, Christine Higham, Elliot Stieglitz
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Cancer Reports
Subjects:
acute lymphocytic leukemia
chronic myeloid leukemia
hematopoietic stem cell transplant
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cnr2.1901

Internet

https://doi.org/10.1002/cnr2.1901

Similar Items